Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium

Abstract

Aim: Recent studies demonstrate that sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i), two classes of antidiabetic drugs, are cardioprotective. However, the mechanisms of these benefits and their comparative efficacy remain unclear. We aimed to compare the effects of these antidiabetic agents on cardiac function, perfusion, and microvascular density using a swine model of chronic myocardial ischemia.

Methods: Chronic myocardial ischemia was induced in Yorkshire swine by ameroid constrictor placement to the left circumflex artery. Two weeks later, pigs were administered vehicle (“CON”, 8 pigs), 300 mg SGLT2i canagliflozin, (“CANA”, 8 pigs), or 100 mg DPP4i sitagliptin (“SIT”, 5 pigs) daily. Five weeks later, pigs were euthanized. Cardiac function, perfusion, collateralization, and protein expression were determined by pressure-volume catheter, microsphere analysis, immunofluorescence, and immunoblotting, respectively.

Results: Compared with SIT, CANA was associated with improved stroke volume and cardiac output, with a trend towards reduced left ventricular stiffness. Both CANA and SIT trended towards improved perfusion compared to CON, but there were no differences between the two treatment groups. SIT was associated with improved capillary density with a trend towards improved arteriolar density compared to CANA. Both CANA and SIT were associated with increased expression of vascular endothelial cadherin compared to CON, without differences in treatment groups. SIT pigs had decreased 5′ adenosine monophosphate-activated protein kinase activation compared to CON and CANA. There was a trend towards increased endothelial nitric oxide synthase activation in the SIT group compared to CON. There were no differences in activation of extracellular signal-regulated kinase 1/2 across groups.

Conclusions: In the setting of chronic myocardial ischemia, canagliflozin is associated with improved cardiac function compared to sitagliptin, with similar effects on perfusion despite differences in microvascular collateralization.

Keywords

Sodium-glucose cotransporter-2 inhibitor / dipeptidyl peptidase-4 inhibitor / coronary disease

References

[1] Lassaletta AD,Sellke FW.Therapeutic neovascularization for coronary disease: current state and future prospects.Basic Res Cardiol2011;106:897-909

[2] Knuuti J,Saraste A.2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC).Eur Heart J2020;41:407-77

[3] Wiviott SD,Bonaca MP.Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med2019;380:347-57

[4] Zinman B,Lachin JM.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med2015;373:2117-28

[5] Perkovic V,Neal B.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med2019;380:2295-306

[6] Lim VG,Arjun S,Long DA.SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart.JACC Basic Transl Sci2019;4:15-26 PMCID:PMC6390729

[7] Baker HE,Luebbe ST.Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization.Basic Res Cardiol2019;114:25 PMCID:PMC6616532

[8] Sayour AA,Loganathan S.Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation.J Transl Med2019;17:127 PMCID:PMC6469222

[9] Sabe SA,Sabra M.Canagliflozin improves myocardial perfusion, fibrosis, and function in a swine model of chronic myocardial ischemia.J Am Heart Assoc2023;12:e028623 PMCID:PMC9973570

[10] Sauvé M,Momen MA.Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.Diabetes2010;59:1063-73 PMCID:PMC2844815

[11] Kubota A,Wang H.DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.J Mol Cell Cardiol2016;91:72-80

[12] Bostick B,Ma L.Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.Metabolism2014;63:1000-11 PMCID:PMC4128682

[13] Sabe SA,Broadwin M.Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: a pilot study.Physiol Rep2023;11:e15744 PMCID:PMC10257079

[14] Gonzalez J,Setoguchi S,Dave CV.Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.Cardiovasc Diabetol2023;22:54 PMCID:PMC9999503

[15] Lyu YS,Kim JH,Jeong MH.Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.Cardiovasc Diabetol2023;22:185 PMCID:PMC10362625

[16] Oh M,Kim SO.Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease.Nucl Med Commun2021;42:972-8

[17] Heidenreich PA,Aguilar D.2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation2022;145:e895-1032

[18] Potz BA,Pavlov VI,Abid MR.Extracellular vesicle injection improves myocardial function and increases angiogenesis in a swine model of chronic ischemia.J Am Heart Assoc2018;7:e008344 PMCID:PMC6220556

[19] Scrimgeour LA,Aboul Gheit A.Extracellular vesicles promote arteriogenesis in chronically ischemic myocardium in the setting of metabolic syndrome.J Am Heart Assoc2019;8:e012617 PMCID:PMC6761642

[20] Aboulgheit A,Zhang Z.Lactobacillus plantarum probiotic induces Nrf2-mediated antioxidant signaling and eNOS expression resulting in improvement of myocardial diastolic function.Am J Physiol Heart Circ Physiol2021;321:H839-49 PMCID:PMC8616611

[21] Elmadhun NY,Chu LM,Feng J.Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.J Thorac Cardiovasc Surg2012;144:1486-93 PMCID:PMC3592386

[22] Bankhead P,Fernández JA.QuPath: open source software for digital pathology image analysis.Sci Rep2017;7:16878 PMCID:PMC5715110

[23] Paolisso P,Gragnano F.Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry.Pharmacol Res2023;187:106597 PMCID:PMC9946774

[24] Forzano I,Lombardi A.SGLT2 inhibitors: an evidence-based update on cardiovascular implications.Expert Opin Investig Drugs2023;32:839-47 PMCID:PMC10591907

[25] Wu YJ,Wang LS.SGLT2 inhibitors: new hope for the treatment of acute myocardial infarction?.Am J Cardiovasc Drugs2022;22:601-13

[26] Choi JG,Skandari MR.First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study.Ann Intern Med2022;175:1392-400 PMCID:PMC10155215

[27] Kaze AD,Kim SC,Paik JM.Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.Cardiovasc Diabetol2022;21:47 PMCID:PMC9491404

[28] Spoladore R,Daus F,Kolios D.Metabolic approaches for the treatment of dilated cardiomyopathy.J Cardiovasc Dev Dis2023;10:287 PMCID:PMC10380730

[29] Lee SJ,Oh HG,Jeong SJ.Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease.J Obes Metab Syndr2019;28:254-61 PMCID:PMC6939702

[30] Banerjee D,Xing H.Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to the myocardium independent of angiogenesis.J Thorac Cardiovasc Surg2023;166:e535-50

[31] Zaha VG.AMP-activated protein kinase regulation and biological actions in the heart.Circ Res2012;111:800-14 PMCID:PMC4397099

[32] Li X,Lu Q.AMPK: a therapeutic target of heart failure-not only metabolism regulation.Biosci Rep2019;39:BSR20181767 PMCID:PMC6328861

[33] Harris DD,Xu CM.Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia.Surgery2024;175:265-70

[34] Hoenig MR,Rosenzweig A.Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1.Curr Mol Med2008;8:754-67

[35] Mone P,Jankauskas SS.SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients.Hypertension2022;79:1633-43 PMCID:PMC9642044

[36] Santulli G,Forzano I.Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart.Hypertension2023;80:1800-9 PMCID:PMC10529735